Molecular and IHC Profiling of PTH Tumors to Evaluate Targeted Agents
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/8/2018 |
| Start Date: | November 24, 2015 |
| End Date: | November 1, 2020 |
| Contact: | Nancy D. Perrier, MD |
| Phone: | 713-792-6940 |
Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents
This is a pilot biomarker study designed to compare frequencies of mutations between groups
of malignant, benign and normal tissue or blood of patients with parathyroid disease and
identify the potential genes showing molecular aberrations as other types of cancer.
of malignant, benign and normal tissue or blood of patients with parathyroid disease and
identify the potential genes showing molecular aberrations as other types of cancer.
The purpose of this study is dual-fold:
1. To determine the differences in clinical behavior and immunohistochemical (IHC)
biomarkers between parathyroid carcinoma (PC), atypical neoplasm (AN) and parathyroid
adenoma (PA). This will allow to use these markers as a diagnostic and screening tool
when evaluating parathyroid tumors.
2. To determine which potential genes can be used in patients with parathyroid tumors for
diagnostic purposes. Genomic analysis of tumor samples will be performed to identify
molecular aberrations for which novel targeted therapies have been recently developed.
1. To determine the differences in clinical behavior and immunohistochemical (IHC)
biomarkers between parathyroid carcinoma (PC), atypical neoplasm (AN) and parathyroid
adenoma (PA). This will allow to use these markers as a diagnostic and screening tool
when evaluating parathyroid tumors.
2. To determine which potential genes can be used in patients with parathyroid tumors for
diagnostic purposes. Genomic analysis of tumor samples will be performed to identify
molecular aberrations for which novel targeted therapies have been recently developed.
Inclusion Criteria:
1. The patient cohort for this study consists of all patients within the prospectively
maintained parathyroid database within the Department of Surgical Oncology at the
University of Texas MD Anderson Cancer Center (MDACC) or from collaborating sites,
with tissue or blood available from 1968-2015, previously consented for the use of the
tissue for research purposes (via Protocols LAB 08-0034, PA11-0695 and LAB03-0320 or
the appropriate external mechanism for collaborating sites).
2. All patients with a known diagnoses of PHPT operated/treated in the Department of
Surgical Oncology of MDACC or at a collaborating site. Patients that have provided
consent for the use of the tissue or blood for research purposes will then be
considered for our study (via Protocol LAB03-0320 and LAB 08-0034 or the appropriate
external mechanism for collaborating sites).
3. All consented patients with known diagnoses of PHPT with a histopathological diagnosis
of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. There
will be no restrictions on age, gender, or ethnicity
4. Selected patients obtained through outside collaboration who meet the selection
criteria for tissue availability and diagnostic suitability for inclusion in the study
(See Criteria 3 for diagnostic criteria).
Exclusion Criteria:
1. Patients without tissue available for analysis.
We found this trial at
1
site
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
